Barbara Haber

5.5k total citations · 1 hit paper
103 papers, 3.2k citations indexed

About

Barbara Haber is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Barbara Haber has authored 103 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hepatology, 46 papers in Epidemiology and 30 papers in Surgery. Recurrent topics in Barbara Haber's work include Hepatitis C virus research (41 papers), Liver Disease Diagnosis and Treatment (23 papers) and Pediatric Hepatobiliary Diseases and Treatments (21 papers). Barbara Haber is often cited by papers focused on Hepatitis C virus research (41 papers), Liver Disease Diagnosis and Treatment (23 papers) and Pediatric Hepatobiliary Diseases and Treatments (21 papers). Barbara Haber collaborates with scholars based in United States, Germany and France. Barbara Haber's co-authors include Rebecca Taub, Linda E. Greenbaum, Philip Rosenthal, Kathleen B. Schwarz, Drew E. Cressman, Robert H. Diamond, Kenneth Mohn, Maureen M. Jonas, Michael R. Narkewicz and Jorge A. Bezerra and has published in prestigious journals such as JAMA, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Barbara Haber

96 papers receiving 3.2k citations

Hit Papers

Letermovir vs Valganciclovir for Prophylaxis of Cytomegal... 2023 2026 2024 2025 2023 25 50 75
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients
    2023 95 citations Ajit P. Limaye, Klemens Budde et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Barbara Haber United States 33 1.7k 1.5k 1.1k 524 467 103 3.2k
Michael Adler Belgium 30 1.7k 1.0× 1.8k 1.2× 716 0.7× 200 0.4× 293 0.6× 81 3.1k
Puja Sakhuja India 29 1.5k 0.9× 1.8k 1.2× 835 0.8× 242 0.5× 349 0.7× 138 2.8k
Michael A. Zimmerman United States 29 1.4k 0.9× 812 0.5× 1.4k 1.3× 341 0.7× 297 0.6× 106 2.8k
Yvon Calmus France 29 1.7k 1.1× 1.1k 0.7× 1.7k 1.5× 231 0.4× 207 0.4× 109 3.1k
Young Oh Kweon South Korea 31 1.4k 0.9× 1.5k 1.0× 1.0k 0.9× 622 1.2× 760 1.6× 161 3.5k
Harry L.A. Janssen Netherlands 37 2.0k 1.2× 2.1k 1.4× 655 0.6× 812 1.5× 151 0.3× 112 3.9k
Spilios Manolakopoulos Greece 32 2.6k 1.6× 2.8k 1.8× 564 0.5× 162 0.3× 214 0.5× 128 3.4k
Elie‐Serge Zafrani France 26 1.4k 0.9× 1.0k 0.7× 586 0.5× 342 0.7× 214 0.5× 55 2.8k
P. Carucci Italy 23 1.5k 0.9× 1.9k 1.2× 623 0.6× 247 0.5× 230 0.5× 71 2.8k
Cara L. Mack United States 35 1.5k 0.9× 1.1k 0.7× 3.1k 2.9× 223 0.4× 1.6k 3.4× 97 4.4k

Countries citing papers authored by Barbara Haber

Since Specialization
Citations

This map shows the geographic impact of Barbara Haber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Haber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Haber more than expected).

Fields of papers citing papers by Barbara Haber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Haber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Haber. The network helps show where Barbara Haber may publish in the future.

Co-authorship network of co-authors of Barbara Haber

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Haber. A scholar is included among the top collaborators of Barbara Haber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Haber. Barbara Haber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Groll, Andreas H., Lara Danziger‐Isakov, Christopher Fraser, et al.. (2025). Cytomegalovirus prophylaxis with letermovir in pediatric (birth to <18 years of age) hematopoietic cell transplant recipients: pharmacokinetics, efficacy, and safety results of a Phase 2b study. Antimicrobial Agents and Chemotherapy. 69(10). e0042025–e0042025.
2.
3.
Limaye, Ajit P., Klemens Budde, Atul Humar, et al.. (2023). Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients. JAMA. 330(1). 33–33. 95 indexed citations breakdown →
4.
5.
Dalgård, Olav, Alain H. Litwin, Oren Shibolet, et al.. (2022). Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection. Journal of Addictive Diseases. 41(3). 213–224. 3 indexed citations
6.
Rini, Brian I., Michael B. Atkins, Elizabeth R. Plimack, et al.. (2021). Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. European Urology Oncology. 5(2). 225–234. 25 indexed citations
7.
Serfaty, Lawrence, Ira M. Jacobson, Jürgen K. Rockstroh, et al.. (2018). The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis. Journal of Viral Hepatitis. 26(3). 329–336. 9 indexed citations
8.
Cui, Shuang, Ellen Tsai, Steven F. EauClaire, et al.. (2013). Evidence From Human and Zebrafish That GPC1 Is a Biliary Atresia Susceptibility Gene. Gastroenterology. 144(5). 1107–1115.e3. 96 indexed citations
9.
Shneider, Benjamin L., John Magee, Jorge A. Bezerra, et al.. (2012). Efficacy of Fat-Soluble Vitamin Supplementation in Infants With Biliary Atresia. PEDIATRICS. 130(3). e607–e614. 66 indexed citations
10.
Rodrigue, James R., William F. Balistreri, Barbara Haber, et al.. (2011). Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children. Hepatology. 53(5). 1468–1475. 18 indexed citations
11.
Jonas, Maureen M., Joan M. Block, Barbara Haber, et al.. (2010). Treatment of Children With Chronic Hepatitis B Virus Infection in the United States. Hepatology. 52(6). 2192–2205. 92 indexed citations
12.
Erlichman, Jessi, et al.. (2009). Biliary atresia: how medical complications and therapies impact outcome. Expert Review of Gastroenterology & Hepatology. 3(4). 425–434. 19 indexed citations
13.
Rodrigue, James R., et al.. (2006). Impact of hepatitis C virus (HCV) infection in children: Quality of life, emotional, and cognitive outcomes. Hepatology. 44(4). 1 indexed citations
14.
Haber, Barbara & Pierre Russo. (2003). Biliary atresia. Gastroenterology Clinics of North America. 32(3). 891–911. 37 indexed citations
15.
Stricker, Tamar, Christian Braegger, Warren P. Bishop, et al.. (2001). More Questions About Growth Hormone in Crohn Disease. Journal of Pediatric Gastroenterology and Nutrition. 33(3). 353–354.
16.
Rand, Elizabeth B., C. M. A. Bijleveld, Steven N. Lichtman, et al.. (1998). The Genetic Basis of the Alagille Syndrome. Journal of Pediatric Gastroenterology and Nutrition. 26(2). 234–236. 2 indexed citations
17.
Du, Keyong, Yong Peng, Linda E. Greenbaum, Barbara Haber, & Rebecca Taub. (1997). HRS/SRp40-Mediated Inclusion of the Fibronectin EIIIB Exon, a Possible Cause of Increased EIIIB Expression in Proliferating Liver. Molecular and Cellular Biology. 17(7). 4096–4104. 63 indexed citations
18.
Bishop, Warren P., C. M. A. Bijleveld, Hans A. Büller, et al.. (1997). Breath Hydrogen Testing for Small Bowel Bacterial Overgrowth‐A Lot of Hot Air?. Journal of Pediatric Gastroenterology and Nutrition. 25(2). 245–246. 1 indexed citations
19.
Paradis, Khazal, C. M. A. Bijleveld, Jan Taminiau, et al.. (1997). Nephropathy of Tyrosinemia and its Longterm Outlook. Journal of Pediatric Gastroenterology and Nutrition. 24(1). 113–114.
20.
Haber, Barbara, et al.. (1995). High levels of glucose-6-phosphatase gene and protein expression reflect an adaptive response in proliferating liver and diabetes.. Journal of Clinical Investigation. 95(2). 832–841. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Adler Breakdown of academic impact, for papers by Puja Sakhuja Breakdown of academic impact, for papers by Michael A. Zimmerman Breakdown of academic impact, for papers by Yvon Calmus Breakdown of academic impact, for papers by Young Oh Kweon Breakdown of academic impact, for papers by Harry L.A. Janssen Breakdown of academic impact, for papers by Spilios Manolakopoulos Breakdown of academic impact, for papers by Elie‐Serge Zafrani Breakdown of academic impact, for papers by P. Carucci Breakdown of academic impact, for papers by Cara L. Mack
Rankless by CCL
2026